SCHEMBL6624148

SCHEMBL6624148

O=C1COCCN1CCc1sccc1NS(=O)(=O)c1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.42
EPHX2 P34913 1/20 0.34
TP53 P04637 1/20 0.33
SLC40A1 Q9NP59 1/20 0.33
POLB P06746 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
NMT1 P30419 1/20 0.32
ACLY P53396 2/20 0.32
APLNR P35414 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 2/20 0.31
KMT2A Q03164 2/20 0.31
MEN1 O00255 1/20 0.31
PRKAB2 O43741 1/20 0.31
PRKAG1 P54619 1/20 0.31
PRKAA2 P54646 1/20 0.31
PRKAA1 Q13131 1/20 0.31
PRKAG3 Q9UGI9 1/20 0.31
PRKAG2 Q9UGJ0 1/20 0.31
PRKAB1 Q9Y478 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6624382 0.94 HSD11B1 (0.37) HSD11B1EPHX2TP53POLBSMN1; SMN2
SCHEMBL6623850 0.89 MAPT (0.38) HSD11B1EPHX2TP53SLC40A1POLB
SCHEMBL6629251 0.85 HSD11B1 (0.47) HSD11B1SMN1; SMN2NMT1LMNAMAPT
SCHEMBL6627716 0.85 PTGES2 (0.39) EPHX2TP53SMN1; SMN2ACLYLMNA
SCHEMBL6702255 0.82 HSD11B1 (0.42) HSD11B1EPHX2TP53SLC40A1POLB
SCHEMBL6623901 0.81 HSD11B1 (0.43) HSD11B1TP53SLC40A1
SCHEMBL3615553 0.80 HSD11B1 (0.61) HSD11B1POLBNMT1MAPTKMT2A
SCHEMBL7084113 0.80 KMT2A (0.49) EPHX2POLBSMN1; SMN2KMT2A
SCHEMBL6625638 0.79 KMT2A (0.38) POLBLMNAKMT2A
SCHEMBL6624772 0.79 HSD11B1 (0.42) HSD11B1SMN1; SMN2NMT1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
WO-2019075394-A1 COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME VANDERKLISH PETER (US) 2019-04-18 WO disclosed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885EPHX2 611/4885TP53 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.